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Background. The neutrophil to lymphocyte ratio (NLR) has been found to be 
predictive of survival outcome in a range of tumours. The purpose of this study 
was to investigate the prognostic value of pre-treatment (NLR) in laryngeal 
squamous cell carcinoma (LSCC) patients. 
 
Methods.  A retrospective analysis of 140 LSCC patients treated between 2005 
and 2010 in the Hull and East Yorkshire Hospitals NHS Trust was carried out. 
Patient records were evaluated and both pretreatment neutrophil and 
lymphocyte counts were documented together with survival data, gender, 
smoking status, nodal status and disease staging. 
 
Results. An elevated NLR was significantly associated with advanced disease 
stage, e.g. node positive and tumours Stage III & IV.  In addition a high NLR was 
significantly associated with poor overall survival but not disease free survival 
on multivariate analysis, with the greatest significance seen in patients with the 
highest NLR. 
 
Conclusion. Pretreatment NLR may serve as a useful prognostic marker in LSCC, 
however a large prospective study is required to determine an optimal NLR cut-
off value.
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In England, the incidence of laryngeal cancer has fallen by 20% since 19901.  
Similar findings have also been observed in Europe with a fall from 45,900 new 
cases in 2006 to 39,900 cases in 20122,3.  Better public health promotion on the 
adverse effects of smoking and drinking alcohol is likely to be a major 
contribution to the observed decrease.  However, the survival rate for patients 
with laryngeal cancer has remained unchanged for the last two decades with a 5-
year relative survival of 65% in England1.  In contrast, the survival rates for 
other head and neck cancer sites such as oral cavity, salivary gland, oropharynx 
and nasopharynx have shown some improvement1.  In order to improve the 
survival outcome of laryngeal cancer patients, alternative ways of assessing the 
best treatment plan are necessary.  
 
Understanding tumour biology is essential in developing optimal treatment and 
management for cancer patients.  In recent years, there have been a number of 
studies investigating the role of inflammation and the immune system in 
tumorigenisis.4,5  Cancer cells are known to evoke an immune response against 
tumour specific antigens, causing an influx of lymphocytes into the tumour 
microenvironment6 and the attempted destruction of the cancer and 
surrounding area lead subsequently to an inflammatory response6.  It is now 
widely recognised that inflammatory cells, such as neutrophils, have a role in 
cancer development and progression by promoting tumour cell growth and 
invasion via the production of pro-angiogenic vascular endothelial growth factor 
(VEGF) 7,36,8,9, as well as remodelling the extracellular matrix via the release of 
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multiple cytokines and chemokines, such as IL-1β, IL-8 and IL127.  Tumour cells 
of various types have been demonstrated to escape immunosurveillance, one of 
the hallmarks of cancer development10, by lymphocyte suppression using a 
number of direct cell:cell mechanisms as well as the release of soluble factors.  
These include the promotion, by the tumour, of  myeloid-derived suppressor 
cells (MDSC) which have the ability to inhibit both innate and adaptive 
immunity.7  Furthermore neutrophils inhibit the suppression of the cytolytic 
activity of T lymphocytes with the magnitude of this suppression being 
proportional to the number of neutrophils present.11  Therefore, an elevated 
neutrophil/lymphocyte ratio (NLR) as a result of neutrophilia and 
lymphocytopenia could be an identifier of poor prognosis in cancer patients. 
 
A number of studies have investigated the relationship between NLR and 
survival of cancer patients including those with renal cell cancer12, sacrcoma13 , 
colorectal 14,15 and oesophageal 16 cancer, which all found patients to have 
poorer outcomes with elevated NLR.  Ikeguchi et al. have even suggested 
incorporating NLR in the prognostic scoring system in colorectal cancer17.  
Despite the positive data from other tumours and the fact that results are readily 
available, at a low cost, as part of the routine pre-treatment investigation only a 
few studies on the prognostic significance of NLR in head and neck cancer have 
been reported18–24, with none of these examining the cancer of the larynx.  The 
aim of this study therefore was to evaluate the prognostic value of NLR in 
patients with laryngeal (SCC). 
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Materials and Methods 
Patients 
A retrospective review of 218 patients with newly diagnosed SCC of the larynx 
admitted between January 2005 to December 2010 from Hull and East Yorkshire 
Hospital NHS Trusts, UK was carried out following ethical approval 
(REC:14/SW/0107; NHS R&D approval R1650).  Patients with concurrent 
infection, chronic inflammatory conditions, long-term immunosuppressive 
medications, synchronous cancer, previous history of cancer, palliative 
treatment and those with no preoperative blood test were excluded from 
analysis.  Medical records of all patients were reviewed and clinical information 
was collected, i.e. age at diagnosis, gender, TNM staging, treatment modalities, 
pre-treatment absolute neutrophil and absolute lymphocyte counts, time to 
recurrence and death.  NLR was calculated as absolute neutrophil count divided 
by absolute lymphocyte count.14,18  All patients were followed up for 5 years or 
until December 2013 or death.   
 
Statistical analysis 
Patient demographics (age, gender, smoking status) and clinical characteristics 
(nodal status, clinical stage, recurrence status) were displayed as frequency 
counts and percentages.  Continuous data were expressed as medians with 
interquartile ranges and clinical stage was categorised into early (stage I and II) 
and late (stage III and IV) stage based on TNM classification using the seventh 
edition of the American Joint Committee on Cancer (AJCC) staging system.  
Continuous variables were analysed using the Mann-Whitney U or Kruskal-
Wallis test as appropriate. 
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For survival analysis, patients were categorised into 4 groups on the basis of NLR 
quartiles where overall survival (OS) and disease-free survival (DFS) were the 
endpoints being assessed.  Kaplan-Meier analysis was employed and compared 
by the log-rank test to determine any significance of NLR on survival.  The Cox 
proportional hazard model was used to evaluate the potential prognostic 
variables and multivariate analysis was carried out on variables which were 
found to be significant on the initial univariate analysis.  A p value <0.05 was 
considered to be statistically significant with all statistics being tested two sided. 
SPSS software v20 (SPSS, Chicago, IL) was used to perform all statistical analyses 
throughout. 
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Out of the initial 218 patients identified, 140 patients were eligible for further 
analysis after excluding 78 patients for reasons indicated in Table 1.  Of the140 
patients, there were 121 males and 19 females with a median age of 66 years 
(range 36-92).  Demographic details and clinical characteristics of the patients 
along with NLR median and quartiles are presented in Table 2.  Laryngeal cancer 
patients with advanced stage disease (III/IV) had a significantly higher NLR 
(2.46) than early stage disease (I/II; 2.07;p=0.006).  No significant differences in 
the NLR were observed for any of the other characteristics. 
 
The effect of NLR on survival 
Using the upper and lower quartile and the median NLR from the whole patient 
cohort as divisions, Kaplan-Meier survival analysis showed that the presence of a 
high NLR in the peripheral circulation (greater than the upper quartile 3.10) was 
associated with poorer OS (p =0.014) but not DFS (p = 0.351;Figure 1 and 2).   
Univariate Cox regression analysis was performed for demographic and clinical 
variables (Table 3) and showed that female gender, nodal positive status and 
advanced clinical stage were all associated with poorer OS and DFS.  NLR  was 
significantly associated with OS (HR, 3.0 95% CI 1.28 – 6.97) but not DFS. 
Subsequently, a multivariate Cox regression analysis was carried out and 
revealed that patients with the highest quartile of NLR had a significantly poorer 
OS (HR, 3.06; 95% CI 1.08 – 8.67) compared to the lowest quartile (Table 4).  
Advanced clinical stage is significantly associated with a poorer OS [HR, 2.46; 
95%CI 1.03 – 5.91) but not DFS.  Patients with node positive disease as well as 
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being a female had significant poorer prognosis for both OS (HR, 2.58; 95% CI 
1.38 – 4.81; HR 2.78 95% CI 1.39 – 5.57, respectively) and DFS (HR, 2.82; 95% CI 
1.55 – 5.11; HR 2.29 95% CI 1.23 – 4.26, respectively) when compared with their 
counterparts. 
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In the current study LSCC patients with a high pretreatment NLR were 
associated with poorer OS.  Advanced disease (stage III/IV) was found to be 
associated with high NLR when compared with early stage disease (stage I/II).  
However, NLR was found to have no predictive value for DFS. 
 
A growing number of studies investigating the association between NLR and 
cancer from different anatomical sites have emerged in recent years.13–16,25–27.  
Studies on sarcoma, colorectal, renal and gastric cancer found that high NLR is 
associated with poor OS13,14,28,29,  DSS15 , PFS 12,18, or DFS30 as well as being a 
positive indicator of cancer recurrence 13,15. Meanwhile,  studies on oral cavity, 
gastric, colorectal, bladder and oesophageal cancers reported NLR had no 
prognostic values in predicting OS 25–27,31, DSS24 or recurrence29.  However, only 
seven studies have examined the relationship of NLR with cancer in the head and 
neck region, of which three were on the nasopharynx 18–20, one on the thyroid 21 
and three on the oral cavity22–24.  Again different outcomes have been reported 
from these studies in part because different survival endpoints have been used, 
i.e. OS, disease-specific survival (DSS) / cancer-specific survival (CSS) and 
progression-free survival (PFS). 
Our findings are comparable with the study by Jankova et al.29 on colorectal 
cancer in which they found a link between high NLR and poor OS but no 
association was found between NLR and recurrence or cancer specific death. 
Within the head and neck studies, He et al.,18 An et al.,19 and Jin et al.20 examined 
patients with newly presenting nasopharyngeal carcinoma (NPC) with 1410, 363 
and 229 patients respectively and all concluded that high NLR was associated 
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with poor survival.  Similar to the current study Jin et al.,20 divided patients into 
groups based on the NLR quartile for comparison, with the same conclusion of 
poor OS being associated with high NLR.  The current study additionally included 
DFS as a further endpoint although no association with NLR was found.  Fang et 
al. and Perisanidis et al. also reported an association of high NLR with poor 
survival for oral cavity cancer patients (n=226 and 97 respectively).  The only 
previous head and neck study examining DFS was by Fang et al., and they also 
observed an association of poor DFS and high NLR.  The thyroid study by Liu et 
al., reported an association between high NLR and tumour volume as well as the 
risk of recurrence but they did not investigate the association between NLR and 
survival.  In contrast to the other head and neck studies, a recent study on oral 
cavity cancer patients by Tsai et al., which included 202 patients, reported NLR 
had no predictive value on survival, however, they did report an association 
between high monocyte count and poor survival. 
 
Given the conflicting results of these studies on NLR and cancer, a systematic 
review and meta-analysis32 was carried out recently by Templeton et al. on 100 
studies including 40,559 patients.  Colorectal, gastroesophageal and 
hepatoceullar carcinoma patients made up the majority of the cohorts in this 
review with 22, 14 and 8 studies respectively.  OS was the most common end 
point studied (n=79), follow by DFS (n= 28), PFS (n = 16) and CSS ( n = 10).  The 
overall conclusion was that high NLR is associated with an adverse OS in many 
solid tumours.  
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One of the reasons for the differences observed in the relationship of NLR to 
survival may be down to the different methods which have been used to identify 
and categorise the NLR cut-off values.  The two methods most commonly used 
are receiver operating characteristic (ROC) curves, and comparison of medians 
and quartiles.  An NLR of 5 has commonly been used as a cut-off value in 
colorectal33 and mesothelioma studies25.  However, the cut-off value used by 
many studies is often not clearly stated as documented by Templeton et al. in 
their meta analysis32.  Furthermore, the underlying aetiology of cancer 
development is different between different cancer sites, for example, 
inflammatory bowel disease has a strong link with colorectal cancer 34, whereas 
cancer of the larynx does not share a similar inflammatory aetiology instead 
smoking-related irritations are th  major risk factor, therefore the NLR cut-off 
could be very different between tumours.  Within head and neck cancer subsites, 
our group has previously demonstrated that the prevalence of tumour 
infiltrating immune cells (CD4, CD8 and Foxp3) were subsite dependent with a 
higher number found in cancer of the oropharynx compared with the larynx35. 
Given the relationship between site specific inflammation and immune response, 
this further supports the idea that site-specific NLR cut-offs are essential. 
 
In the present study, high NLR was found to relate significantly with a poorer OS 
but not DFS.  Further investigations are not only needed to examine NLR and its 
clinical value but also the underlying mechanisms.  Determination of NLR post 
treatment would also be of value as it might provide an insight into the response 
of the immune system following treatment, these data were not available as this 
was a retrospective analysis and the post treatment bloods were not analysed 
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routinely.  If NLR normalised after treatment, this could mean that NLR is not 
only a prognostic marker but also a possible marker for monitoring disease 
progression.  With these data available, it might allow patients to be further 
categorised based on the NLR in addition to the current TNM staging system and 
thus enable more tailored treatments to be administered.  The retrospective 
nature of the current study meant that a proportion of patients were excluded 
due to the unavailability of pretreatment blood tests results.  A large well 
designed prospective study is needed to address these clinical and basic science 
questions to provide definitive clinical prognostic information on patient 
outcome.   
Page 12 of 22
































































1. Profile of Head and Neck Cancers in England : Incidence, Mortality and 
Survival. 2010; at <www.ncin.org.uk/view?rid=69> [Accessed 17 Feburary 
2015] 
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and 
mortality patterns in Europe: estimates for 40 countries in 2012. Eur J 
Cancer 2013; 49: 1374–403. 
3. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and 
mortality in Europe in 2006. Ann Oncol 2007; 18: 581–92. 
4. Balkwill F & Mantovani a. Inflammation and cancer: back to Virchow? 
Lancet 2001; 357: 539–45. 
5. Coussens L, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867. 
6. Nagtegaal ID, Marijnen CAM, Kranenbarg EK et al. Local and distant 
recurrences in rectal cancer patients are predicted by the nonspecific 
immune response ; specific immune response has only a systemic effect - a 
histopathological and immunohistochemical study. BMC Cancer 2001; 1:7 
7. Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: 
Implications for cancer surveillance and immunotherapy. 
Oncoimmunology 2012; 1: 717–725. 
8. Teramukai S, Kitano T, Kishida Y et al. Pretreatment neutrophil count as an 
independent prognostic factor in advanced non-small-cell lung cancer: an 
analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 
2009; 45: 1950–8. 
9. Kusumanto YH, Dam WA, Hospers GAP, Meijer C, Mulder NH. Platelets and 
granulocytes, in particular the neutrophils, form important compartments 
for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 
283–7. 
10. Hanahan D & Weinberg RA. Hallmarks of cancer: the next generation. Cell 
2011; 144: 646–74. 
11. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T 
lymphocyte activity in vitro by autologous peripheral blood granulocytes. J 
Immunol 1985; 134: 230–234. 
12. Santoni M, De Giorgi U, Iacovelli R et al. Pre-treatment neutrophil-to-
lymphocyte ratio may be associated with the outcome in patients treated 
with everolimus for metastatic renal cell carcinoma. Br J Cancer 2013; 109: 
1755–9. 
Page 13 of 22































































13. Szkandera J, Absenger G, Liegl-Atzwanger B et al. Elevated preoperative 
neutrophil/lymphocyte ratio is associated with poor prognosis in soft-
tissue sarcoma patients. Br J Cancer 2013; 108: 1677–83. 
14. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte 
ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 
181–4. 
15. Toh E, Wilson J, Sebag-Montefiore D, Botterill I. Neutrophil:lymphocyte 
ratio as a simple and novel biomarker for prediction of locoregional 
recurrence after chemoradiotherapy for squamous cell carcinoma of the 
anus. Colorectal Dis 2014; 16: O90–7. 
16. Sato H, Tsubosa Y, Kawano T. Correlation between the pretherapeutic 
neutrophil to lymphocyte ratio and the pathologic response to 
neoadjuvant chemotherapy in patients with advanced esophageal cancer. 
World J Surg 2012; 36: 617–22. 
17. Ikeguchi M, Urushibara SI, Shimoda R et al. Inflammation-based prognostic 
scores and nutritional prognostic index in patients with locally-advanced 
unresectable colorectal cancer. World J Surg Oncol 2014; 12: 210. 
18. He J, Shen G, Ren Z, Qin H, Cui C. Pretreatment levels of peripheral 
neutrophils and lymphocytes as independent prognostic factors in 
patients with nasopharyngeal carcinoma. Head Neck 2012; 1769–1776.  
19. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to 
lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. 
Tumour Biol 2011; 32: 317–24. 
20. Jin Y, Ye X, He C, Zhang B, Zhang Y. Pretreatment neutrophil-to-lymphocyte 
ratio as predictor of survival for patients with metastatic nasopharyngeal 
carcinoma. Head Neck 2013; 1–7 
21. Liu CL, Lee JJ, Liu TP et al. Blood neutrophil-to-lymphocyte ratio correlates 
with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 
2013; 107: 493–497. 
22. Perisanidis C, Kornek G, Pöschl PW et al. High neutrophil-to-lymphocyte 
ratio is an independent marker of poor disease-specific survival in patients 
with oral cancer. Med Oncol 2013; 30: 334. 
23. Fang HY, Huang XY, Chien HT et al. Refining the role of preoperative C-
reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous 
cell carcinoma. Laryngoscope 2013; 123: 2690–9. 
24. Tsai YD, Wang CP, Chen CY et al. Pretreatment circulating monocyte count 
associated with poor prognosis in patients with oral cavity cancer. Head 
Neck 2014; 36: 947–53. 
Page 14 of 22































































25. Meniawy TM, Creaney J, Lake RA, Nowak AK. Existing models, but not 
neutrophil-to-lymphocyte ratio, are prognostic in malignant 
mesothelioma. Br J Cancer 2013; 109: 1813–20. 
26. Lee DY, Hong SW, Chang YG, Lee WY, Lee B. Clinical significance of 
preoperative inflammatory parameters in gastric cancer patients. J Gastric 
Cancer 2013; 13: 111–6. 
27. Demirtaş A, Sabur V, Akinsal EC et al. Can Neutrophil-Lymphocyte Ratio 
and Lymph Node Density Be Used as Prognostic Factors in Patients 
Undergoing Radical Cystectomy? Scientific World Journal 2013; 
2013:703579 
28. Wang S, Zhang Z, Fang F et al. The neutrophil/lymphocyte ratio is an 
independent prognostic indicator in patients with bone metastasis. Oncol 
Lett 2011; 2: 735–740. 
29. Jankova L, Dent OF, Chan C, Chapuis P, Clarke SJ. Preoperative 
neutrophil/lymphocyte ratio predicts overall survival but does not predict 
recurrence or cancer-specific survival after curative resection of node-
positive colorectal cancer. BMC Cancer 2013; 13: 442. 
30. Jung MR, Park YK, Jeong O et al. Elevated preoperative neutrophil to 
lymphocyte ratio predicts poor survival following resection in late stage 
gastric cancer. J Surg Oncol 2011; 104: 504–10. 
31. Rashid F, Waraich N, Bhatti I et al. A pre-operative elevated neutrophil: 
lymphocyte ratio does not predict survival from oesophageal cancer 
resection. World J Surg Oncol 2010; 8: 1. 
32. Templeton AJ, McNamara MG, Šeruga B et al. Prognostic role of neutrophil-
to-lymphocyte ratio in solid tumors: a systematic review and meta-
analysis. J Natl Cancer Inst 2014; 106: dju124. 
33. Li MX, Liu XM, Zhang XF et al. Prognostic role of neutrophil-to-lymphocyte 
ratio in colorectal cancer: a systematic review and meta-analysis. Int J 
Cancer 2014; 134: 2403–13. 
34. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients 
with ulcerative colitis: a meta-analysis of population-based cohort studies. 
Clin Gastroenterol Hepatol 2012; 10: 639–45. 
35. Green VL, Michno A, Stafford ND, Greenman J. Increased prevalence of 
tumour infiltrating immune cells in oropharyngeal tumours in comparison 
to other subsites: relationship to peripheral immunity. Cancer Immunol 
Immunother 2013; 62: 863–73.  
 
Page 15 of 22

































































Page 16 of 22































































Table 1 - Indications for exclusion of patients from the study 
 
Indications n 
No pre-treatment blood tests 25 
Previous history of cancer 21 
Concurrent infection 10 
Synchronous cancer 8 
Palliative care 7 
Long term immunosuppressant medications / 
chronic inflammatory conditions 
6 
Declined treatment 1 
Total 78 
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No. (%) NLR median 
(25th , 75th ) 
Total  140 2.41 (1.78, 3.10) 
   
Age, yr  p = 0.357 
≤60 48 (34.3%) 2.50 (1.85, 3.27) 
>60 92 (65.7%) 2.35 (1.75, 2.98) 
   
Gender  p = 0.324 
Male 121 (86.4%) 2.45 (1.82, 3.16) 
Female 19 (14.6%) 2.06 (1.68, 2.77) 
   
Smoking status  p =0 .768 
Non or Ex-smoker 60 (42.9%) 2.37 (1.85, 2.88) 
Smoker 74 (52.9%) 2.46 (1.76, 3.28) 
Missing data 6 (4.3%) - 
   
Nodal status  p =0 .447 
N0 105 (75%) 2.44 (1.74, 2.95) 
N+ 35 (25%) 2.36 (1.95, 3.38) 
   
   
Disease stage  p =0 .006 
Stage I/II 57 (40.7%) 2.07 (1.60, 2.81) 
Stage III/IV 83 (59.3%) 2.46 (2.03, 3.38) 
   
Recurrence  p =  0.186 
Yes 41 (29.3%) 2.47 (2.02, 3.35) 
No 99 (70.7%) 2.36 (1.75, 2.93) 
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Figure 1 Kaplan-Meier survival analysis compared the four NLR groups based on 




Page 19 of 22



































































Figure 2 Kaplan-Meier survival analysis compared the four NLR groups based on 
NLR quartiles, showing no association between high NLR and DFS 
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No. of events HR (95% CI) p No. of events HR (95% CI) p 
Gender    <0.01   <0.01 
Male 121 41   47   
Female 19 19 2.81 (1.42 – 5.54)  13 2.53 (1.36 – 4.69)  
Age    0.24   0.87 
≤60 48 21   22   
>60 92 28 0.72 (0.41 – 1.26)  38 0.957 (0.57 – 1.62)  
Smoking    0.75   0.72 
Non or ex-smoker 60 29   24   
Smoker 74 22 1.10 (0.62 – 1.96)  32 1.10 (0.65 – 1.87)  
Nodal Status    <0.01   <0.01 
N0 105 26   34   
N+ 35 23 4.26 (2.41 – 7.51)  26 3.65 (2.18 – 6.13)  
Clinical stage    <0.01   0.01 
Stage I and II 57 10   15   
Stage III and IV 83 43 4.75 (2.22 – 10.17)  45 2.61 (1.45 – 4.68)  
        
NLR    0.03   0.37 
≤1.78 35 8    12   
~2.41 35 15 3.33  (0.97 – 5.45) 0.02 16 1.45 (0.69 – 3.07) 0.33 
~3.10 35 13 2.80  (0.72 – 4.21) 0.05 14 1.17 (0.54 – 2.53) 0.69 
>3.10 35 17 4.64 (1.28 – 6.97) <0.01 18 1.85 (0.89 – 3.84) 0.10 
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Table 4 Multivariate Cox regression analysis for OS and DFS in patients with laryngeal SCC 
 
  OS DFS 
HR (95% CI) p HR (95% CI) p 
Gender      
Male 121  <0.01  <0.01 
Female 19 2.78 (1.39 – 5.57)  2.29 (1.23 – 4.26)  
Nodal Status      
N0   <0.01  <0.01 
N+  2.58 (1.38 – 4.81)  2.82 (1.55 – 5.11)  
Staging      
Stage I and II 57  0.04  0.18 
Stage III and IV 83 2.46 (1.03 – 5.91)  1.59 (0.81 – 3.14)  
      
NLR   0.18   
≤1.78 35   - - 
~2.41 35 2.01 (0.70 – 5.76) 0.19 - - 
~3.10 35 2.6 (0.91 – 7.31) 0.08 - - 
>3.10 35 3.06 (1.08 – 8.67) 0.04 - - 
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